Parkinson’s Disease

Parkinson's disease is a progressive neurodegenerative disorder characterized by the gradual degeneration of dopamine-producing neurons in the brain. This loss of dopamine disrupts the normal balance of neurotransmitters, leading to the hallmark symptoms of the disease, which include tremors, stiffness, slowness of movement, and postural instability. As the disease advances, it can also affect cognitive functions and lead to complications such as difficulties with balance and coordination. While the exact cause of Parkinson's disease remains unknown, it is believed to involve a combination of genetic and environmental factors. Treatments primarily focus on managing symptoms and improving quality of life, using medications, physical therapy, and in some cases, surgical interventions. Research continues to explore more effective therapies and potential cures for this challenging condition.

Learn more

Patient Recruitment Ended for Parkinson's Disease Treatment Study

We are excited to announce the launch of a clinical trial for TB006, an innovative treatment for Parkinson's disease, starting in November 2024. This study aims to assess the efficacy and safety of TB006 in managing Parkinson’s disease symptoms and improving quality of life. Please visit clinicaltrial.gov (NCT06773962) for more information.

Please note that enrollment for this specific clinical trial has now officially closed. We are incredibly grateful to the patients and clinicians who have contributed to this milestone.

While we are no longer accepting new participants for this study, we are actively preparing for the next phase of our research. We will share details regarding the launch of new clinical trials as soon as they become available. In the meantime, we encourage you to stay in touch with your neurologist and monitor this space for upcoming opportunities to participate in our mission to treat Parkinson’s disease.

Eligibility Criteria (Sourcing from clinicaltrial.gov)